Heim0853 • HKG
add
MicroPort Scientific Corp
Við síðustu lokun
11,26 $
Dagbil
11,11 $ - 11,44 $
Árabil
5,21 $ - 16,28 $
Markaðsvirði
21,44 ma. HKD
Meðalmagn
13,99 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
HKG
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | jún. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 273,77 m. | -2,00% |
Rekstrarkostnaður | 153,68 m. | -14,80% |
Nettótekjur | -23,30 m. | 51,87% |
Hagnaðarhlutfall | -8,51 | 50,89% |
Hagnaður á hvern hlut | — | — |
EBITDA | 26,04 m. | 99,76% |
Virkt skatthlutfall | -86,95% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | jún. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 957,62 m. | -7,63% |
Heildareignir | 3,77 ma. | -0,59% |
Heildarskuldir | 2,59 ma. | 3,36% |
Eigið fé alls | 1,18 ma. | — |
Útistandandi hlutabréf | 1,85 ma. | — |
Eiginfjárgengi | 33,12 | — |
Arðsemi eigna | 0,04% | — |
Ávöxtun eigin fjár | 0,05% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | jún. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -23,30 m. | 51,87% |
Handbært fé frá rekstri | -5,77 m. | 65,49% |
Reiðufé frá fjárfestingum | -3,17 m. | 96,31% |
Reiðufé frá fjármögnun | 33,95 m. | 201,05% |
Breyting á handbæru fé | 25,75 m. | 118,43% |
Frjálst peningaflæði | 12,88 m. | 421,18% |
Um
MicroPort is a multinational medical technology company with headquarters in Shanghai; Irvine, California; and Clamart, France. Founded in 1998, the company designs and produces medical devices across multiple therapeutic areas including interventional cardiology, orthopedics, cardiac rhythm management, electrophysiology, neurovascular intervention, structural heart disease, surgical robotics, and critical care.
MicroPort completed its initial public offering on the Hong Kong Stock Exchange in 2010 and has since established multiple specialized subsidiaries focused on distinct therapeutic areas, with several completing separate public listings. Recognized as one of the global Medtech Big 100 companies, MicroPort's coronary intervention products have been implanted in over 10 million patients globally since its founding, with devices distributed in over 90 countries across Asia, North America, Latin America, Europe, the Middle East, and Africa. Wikipedia
Framkvæmdastjóri
Stofnsett
1998
Vefsvæði
Starfsfólk
6.287